SUPPLEMENTARY MATERIAL

Supplementary Table 1. Laboratory results and skin tests

4h after acute event	Tryptase	62.9 µg/L
3 days after event	Tryptase	5.3 µg/L
	Total IgE	1,682 kU/L
	sIgEEthyleenoxide (k78)	<0.10 kU/L
	sIgE Latex (k82)	<0.10 kU/L
	sIgEChloorhexidine (c8)	<0.10 kU/L
	sIgE Galactose-alfa-1,3-galactose (o215)	0.24 kU/L
4 months after event	sIgE Mouse-epithelium (e71)	45.50 kU/L
	sIgE Mouse-urine proteins (e72)	29.50 kU/L
	sIgE Mouse serum proteins (e76)	22.60 kU/L
	sIgE Mouse complete (e88)	48.70 kU/L
	sIgE Guinea pig-epithelium (e6)	5,50 kU/L
	sIgE hamster-epithelium (e84)	9,72 kU/L
	sIgE rat-epithelium/serum proteins/urine proteins (e87)	14,4 kU/L
Skin tests 4 months after event	Histamine (10 mg/ml) positive control	+(6 mm)
	Saline negative control	-
	Chlorhexidine (2%, 20 mg/ml)	-
	infliximab (Inflectra® 10 mg/ml)	-
	adalimumab (Humira® 100 mg/ml)	-

doi: 10.18176/jiaci.0676

	vedolizumab (Entyvio® 60 mg/ml)	+ (6 mm)
	sulesomab (Leukoscan® 0,31 mg/1.5 ml)	+(4 mm)
	MA-8H9D7 mouse monoclonal (2 mg/ml)	+ (4 mm)
	cetuximab (Erbitux® 5 mg/ml)	+ (4 mm)

Total and specific IgE (sIgE) was determined using a commercially available kit (Immunocap, Phadia, Sweden). Skin test results (positive or negative) are shown together with mm induration for skin prick tests (SPT) and increase in induration diameter for intradermal tests (IDT). For chloorhexidine SPT undiluted and intradermal testing (IDT) 1/10,000 diluted was performed. For infliximab adalimumab, SPT with undiluted and IDT with a 1/10 dilution was performed. Vedolizumab was positive with ID 1/10000 mg/ml on IDT, Sulesomab with1/1000 mg/ml on SPT, MA-8HPD7 with 1/1000 SPT and Cetuximab with 1/10000 IDT.

doi: 10.18176/jiaci.0676